Table S1.
Example of a random choice task. Twelve random choice tasks without an “opt-out” or “no-treatment” option were included in the discrete choice experiment.
| DMARD characteristic | Medicine 1 | Medicine 2 |
|---|---|---|
| Route of administration | Oral (tablets/capsules) | Subcutaneous (injection in the upper leg or abdomen) |
| Frequency of administration | Weekly | Monthly |
| Onset of action | Six weeks | 12 weeks |
| Risk of cancer (eg, skin cancer with favorable prognostic factors) | No risk | 1 of 1,000 patients (0.1%) |
| Risk of liver injury (eg, higher levels of liver damage markers) | 1 of 1,000 patients (0.1%) | No risk |
| Risk of serious infections (eg, hospital admissions/discontinuation of anti-rheumatic drugs) | No risk | 1 of 1,000 patients (0.1%) |
| Chance of efficacy | 80% | 60% |
| Preference for Medicine 1 or Medicine 2 | □ | □ |
Abbreviation: DMARD, disease-modifying antirheumatic drug.